Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2

Molecular Pharmacology

Volumn 84, Issue 4, 2013, Pages 551-561

  Zweemer, Annelien J M ^a   Nederpelt, Indira ^a   Vrieling, Hilde ^a   Hafith, Sarah ^a   Doornbos, Maarten L J ^a   De Vries, Henk ^a   Abt, Jeffrey ^b   Gross, Raymond ^b   Stamos, Dean ^b   Saunders, John ^b   Smit, Martine J ^c   IJzerman, Adriaan P ^a   Heitman, Laura H ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b VERTEX PHARMACEUTICALS   (United States)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; IODINE 125; N [2 [[1 [4 (1,3 BENZODIOXOL 5 YL) 4 HYDROXYCYCLOHEXYL] 4 ETHOXY 3 PYRROLIDINYL]AMINO] 2 OXOETHYL] 3 (TRIFLUOROMETHYL)BENZAMIDE; RADIOLIGAND;

ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ISOTOPE LABELING; PRIORITY JOURNAL;

BINDING SITES; CELL LINE; CHEMOKINE CCL2; CHEMOKINES; HUMANS; PROTEIN BINDING; PYRROLIDINES; RECEPTORS, CCR2;

EID: 84884691963     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.086850     Document Type: Article

References (42)

1. Andrews G, Jones C, and Wreggett KA (2008) An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol Pharmacol 73:855-867. (Pubitemid 351397890)
2. Berkhout TA, Blaney FE, Bridges AM, Cooper DG, Forbes IT, Gribble AD, Groot PH, Hardy A, Ife RJ, and Kaur R et al. (2003) CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem 46:4070-4086. (Pubitemid 37122451)
3. Bhangoo S, Ren D, Miller RJ, Henry KJ, Lineswala J, Hamdouchi C, Li B, Monahan PE, Chan DM, and Ripsch MS et al. (2007) Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors. Mol Pain 3:38.
4. Boring L, Gosling J, Cleary M, and Charo IF (1998) Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-897. (Pubitemid 28410911)
5. Brodmerkel CM, Huber R, Covington M, Diamond S, Hall L, Collins R, Leffet L, Gallagher K, Feldman P, and Collier P et al. (2005) Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 175:5370-5378. (Pubitemid 41456423)
6. Buntinx M, Hermans B, Goossens J, Moechars D, Gilissen RA, Doyon J, Boeckx S, Coesemans E, Van Lommen G, and Van Wauwe JP (2008) Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2- thioxo-2, 3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2. J Pharmacol Exp Ther 327:1- 9.
7. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. Cherney RJ, Mo R, Meyer DT, Nelson DJ, Lo YC, Yang G, Scherle PA, Mandlekar S, Wasserman ZR, and Jezak H, et al. (2008) Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J Med Chem 51:721-724. (Pubitemid 351304681)
9. de Kruijf P, van Heteren J, Lim HD, Conti PG, van der Lee MM, Bosch L, Ho KK, Auld D, Ohlmeyer M, and Smit MJ, et al. (2009) Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor. J Pharmacol Exp Ther 329:783-790.
10. Doyon J, Coesemans E, Boeckx S, Buntinx M, Hermans B, Van Wauwe JP, Gilissen RA, De Groot AH, Corens D, and Van Lommen G (2008) Discovery of potent, orally bioavailable small-molecule inhibitors of the human CCR2 receptor. ChemMedChem 3:660-669.
11. El-Asmar L, Springael JY, Ballet S, Andrieu EU, Vassart G, and Parmentier M (2005) Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 67:460-469. (Pubitemid 40216739)
12. Fantuzzi L, Borghi P, Ciolli V, Pavlakis G, Belardelli F, and Gessani S (1999) Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the regulation of the chemotactic response. Blood 94:875-883. (Pubitemid 29361817)
13. Hall SE, Mao A, Nicolaidou V, Finelli M, Wise EL, Nedjai B, Kanjanapangka J, Harirchian P, Chen D, and Selchau V et al. (2009) Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol Pharmacol 75:1325-1336.
14. Jimenez F, Quinones MP, Martinez HG, Estrada CA, Clark K, Garavito E, Ibarra J, Melby PC, and Ahuja SS (2010) CCR2 plays a critical role in dendritic cell maturation: possible role of CCL2 and NF-kappa B. J Immunol 184:5571-5581.
15. Kenakin T and Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265-304.
16. Kredel S, Wolff M, Hobbie S, Bieler M, Gierschik P, and Heilker R (2011) High-content analysis of CCR2 antagonists on human primary monocytes. J Biomol Screen 16:683-693.
17. Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G proteincoupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
18. Luster AD (1998) Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 338:436-445.
19. Magnan R, Escrieut C, Gigoux V, De K, Clerc P, Niu F, Azema J, Masri B, Cordomi A, and Baltas M et al. (2013) Distinct CCK-2 receptor conformations associated with β-arrestin-2 recruitment or phospholipase-C activation revealed by a biased antagonist. J Am Chem Soc 135:2560-2573.
20. Mahad DJ and Ransohoff RM (2003) The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 15 :23-32. (Pubitemid 36092176)
21. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, Weatherhead GS, Lapierre JM, and Dankwardt J et al. (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 275: 25562-25571.
22. Monteclaro FS and Charo IF (1997) The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand. J Biol Chem 272: 23186-23190. (Pubitemid 27392450)
23. Moree WJ, Kataoka K, Ramirez-Weinhouse MM, Shiota T, Imai M, Tsutsumi T, Sudo M, Endo N, Muroga Y, and Hada T, et al. (2008) Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series. Bioorg Med Chem Lett 18 :1869-1873. (Pubitemid 351380903)
24. Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, and Wright TJ et al. (2008) Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 74:1193-1202.
25. Pease JE, Wang J, Ponath PD, and Murphy PM (1998) The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP- 1alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation. J Biol Chem 273:19972-19976. (Pubitemid 28377545)
26. Quinones MP, Estrada CA, Kalkonde Y, Ahuja SK, Kuziel WA, Mack M, and Ahuja SS (2005) The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med (Berl) 83:672-681. (Pubitemid 41225109)
27. Rosenkilde MM and Schwartz TW (2006) GluVII:06 - a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors. Curr Top Med Chem 6:1319-1333. (Pubitemid 44144918)
28. Salchow K, Bond ME, Evans SC, Press NJ, Charlton SJ, Hunt PA, and Bradley ME (2010) A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol 159:1429-1439.
29. Samson M, LaRosa G, Libert F, Paindavoine P, Detheux M, Vassart G, and Parmentier M (1997) The second extracellular loop of CCR5 is the major determinant of ligand specificity. J Biol Chem 272:24934-24941. (Pubitemid 27415669)
30. Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, de Graaf C, Vischer HF, and Leurs R (2012) Pharmacological modulation of chemokine receptor function. Br J Pharmacol 165:1617-1643.
31. Shin N, Baribaud F, Wang K, Yang G, Wynn R, Covington MB, Feldman P, Gallagher KB, Leffet LM, and Lo YY et al. (2009) Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2. Biochem Biophys Res Commun 387:251-255.
32. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85. (Pubitemid 16258399)
33. Sohy D, Parmentier M, and Springael JY (2007) Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem 282:30062-30069. (Pubitemid 350035295)
34. Springael JY, Le Minh PN, Urizar E, Costagliola S, Vassart G, and Parmentier M (2006) Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol 69:1652-1661.
35. Struthers M and Pasternak A (2010) CCR2 antagonists. Curr Top Med Chem 10: 1278-1298.
36. Surgand JS, Rodrigo J, Kellenberger E, and Rognan D (2006) A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62:509-538. (Pubitemid 43054370)
37. Vauquelin G, Van Liefde I, Birzbier BB, and Vanderheyden PM (2002) New insights in insurmountable antagonism. Fundam Clin Pharmacol 16:263-272. (Pubitemid 35205336)
38. White FA, Bhangoo SK, and Miller RJ (2005) Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov 4:834-844. (Pubitemid 41553964)
39. Xi B, Yu N, Wang X, Xu X, and Abassi YA (2008) The application of cell-based label-free technology in drug discovery. Biotechnol J 3:484-495. (Pubitemid 351618734)
40. Xue C MB, Metcalf B, Feng H, Cao G, Huang T, Zheng C, Robinson DJ, Han A (2004), inventors, Incyte Corporation, assignee. 3-Aminopyrrolidine derivatives as modulators of chemokine receptors. PCT/US2003/037946. 1994 Jun 17.
41. Yu N, Atienza JM, Bernard J, Blanc S, Zhu J, Wang X, Xu X, and Abassi YA (2006) Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors. Anal Chem 78: 35-43. (Pubitemid 43050137)
42. Zou D, Zhai HX, Eckman J, Higgins P, Gillard M, Knerr L, Carre S, Pasau P, Collart P, and Grassi J et al. (2007) Novel, acidic CCR2 receptor antagonists: from hit to lead. Lett Drug Des Discov 4:185-191. (Pubitemid 46474158)